Personalised Medicine: Is Horizon Discovery's business model a better approach?




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Personalised Medicine: Is Horizon Discovery's business model a better approach?
Released on: July 08, 2015. © PTV
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
In This Episode:
    Advances in genomics have led to the active development of targeted therapeutics and companion diagnostics that leverage knowledge of an individual’s genetic profile to create a more personalized approach to healthcare.
  • Summary
  • Transcript
  • Participants
  • Company
Advances in genomics have led to the active development of targeted therapeutics and companion diagnostics that leverage knowledge of an individual’s genetic profile to create a more personalized approach to healthcare. This makes it possible to identify those most susceptible to disease, to determine how a given patient will respond to a particular therapy, and how best to match drugs to patients based on their genetic profiles. Horizon supply research tools to organisations engaged in genomics research and the development of personalised medicines. CEO Darrin Disley explains to PharmaVentures' CEO, Dr Fintan Walton how Horizon aspires to provide science-driven research solutions that lead to the advancement in the understanding of the genetic basis of disease and the delivery of better healthcare outcomes for patients.
Advances in genomics have led to the active development of targeted therapeutics and companion diagnostics that leverage knowledge of an individual’s genetic profile to create a more personalized approach to healthcare. This makes it possible to identify those most susceptible to disease, to determine how a given patient will respond to a particular therapy, and how best to match drugs to patients based on their genetic profiles. Horizon supply research tools to organisations engaged in genomics research and the development of personalised medicines. CEO Darrin Disley explains to PharmaVentures' CEO, Dr Fintan Walton how Horizon aspires to provide science-driven research solutions that lead to the advancement in the understanding of the genetic basis of disease and the delivery of better healthcare outcomes for patients.
Darrin Disley
Horizon Discovery
Dr. Darrin M Disley Chief Executive Officer and President Darrin is a life scientist who has been involved in the start-up and growth of a number of business ventures. He has a track record of raising c$200 million business financing from grant, angel, corporate, venture capital and public market sources as well as closing c$350 million of product, service, and licensing deals. In 2012, he was named Business Leader of the Year at the European Life Science Awards and in 2014 was name Executive of the Year at the Scrip Awards a global award recognising leadership in biotechnology and pharmaceutical companies and Entrepreneur of the Year at the UK Quoted Companies Awards. Darrin holds a PhD in Biotechnology from the University of Cambridge has been the author of numerous papers, patents and conference abstracts and has been an advisor on biotech commercialisation strategies around the world. Darrin supports academic, business plan competition and mentoring programs in the UK via the Professor Christopher R Lowe Carpe Diem Enterprise Fund and is an Entrepreneur in Residence at the Judge Business School and Enterprise Fellow at the Department of Chemical Engineering and Institute of Biotechnology both at the University of Cambridge. He is currently Chairman of GeoSpock Ltd and Desktop Genetics Ltd two Cambridge technology start-ups as well as an Investment Advisory Board member of the Home Run SEIS/EIS Fund managed by Boundary Capital Ltd. Recently he joined the advisory boards of the Cambridge Phenomenon Ltd, Biotech and Money Ltd and the Cambridge Science Centre organisations aimed at promoting the thriving UK life science industry and the role of science in education and social mobility.
Horizon Discovery Ltd
Horizon Discovery Limited (Horizon) is a leading provider of research tools to support translational genomics research and the development of personalized medicines. The Company’s proprietary rAAV gene-editing technology, GENESIS, is industry-leading. Using GENESIS, Horizon is able to alter any endogenous gene sequence of a human or mammalian cell line quickly, reliably and without introducing unwanted and confounding genotypes and/or phenotypes. Founded in 2007, Horizon has become one of the fastest growing biotechnology companies in Europe and now occupies a 20,000 sq. ft. of state-of-art research facility in Cambridge, UK. The company has grown its top-line revenue by greater than 100% every year since foundation, growth that is built upon a customer base that includes 100 academic, biotechnology, diagnostic and pharmaceutical companies. The Company is rapidly leveraging a strong intellectual property, technology and customer base to develop new equity assets (shares, milestones, product royalties) aimed at driving a non-organic growth in its share price. Horizon scientific founders and advisors have been at the forefront of the first test cases for personalized medicine in the field of colorectal cancer and are leading the COLTHERES clinical consortium defining the road-map for the development and diagnosis on new therapeutic regimens for cancer patients.